4-[4-(2-fluoro-benzenesulfonyl)-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl]-piperazine-1-carboxylic acid tert-butyl ester | 853642-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[4-(2-fluoro-benzenesulfonyl)-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl]-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[4-(2-fluorophenyl)sulfonyl-2,2-dimethyl-3H-1,4-benzoxazin-8-yl]piperazine-1-carboxylate
• CAS: 853642-88-3
• 化学式: C₂₅H₃₂FN₃O₅S
• 分子量: 505.611
• InChiKey: GKGJBYAECNVDGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  87.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-[4-(2-fluoro-benzenesulfonyl)-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl]-piperazine-1-carboxylic acid tert-butyl ester 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 4-(2-fluoro-benzenesulfonyl)-2,2-dimethyl-8-piperazin-1-yl-3,4-dihydro-2H-benzo[1,4]oxazine
  参考文献：
  名称：

  3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists

  摘要：

  A series of novel 3,4-dihydro-2H-benzo[1,4]oxazine derivatives has been designed and synthesized as 5-HT6 receptor antagonists. Many of the compounds displayed subnanomolar affinities for the 5-HT6 receptor and good brain penetration in rats. The relationship of structure and lipophilicity to hERG inhibition of this series of compounds is discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.093
• 作为产物：
  描述：

  2-氨基-6-溴苯酚 在 tris(dibenzylideneacetone)dipalladium (0) 吡啶 、 dimethyl sulfide borane 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 生成 4-[4-(2-fluoro-benzenesulfonyl)-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl]-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists

  摘要：

  A series of novel 3,4-dihydro-2H-benzo[1,4]oxazine derivatives has been designed and synthesized as 5-HT6 receptor antagonists. Many of the compounds displayed subnanomolar affinities for the 5-HT6 receptor and good brain penetration in rats. The relationship of structure and lipophilicity to hERG inhibition of this series of compounds is discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.093

文献信息

• Benzoxazine derivatives and uses thereof
  申请人：Berger Jacob

  公开号：US20050124613A1

  公开（公告）日：2005-06-09

  Compounds of the formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X, Y and m are as defined herein. Also provided are compositions comprising, methods for using, and methods for preparing compound of formula (I).

  化合物的公式(I)：或其药学上可接受的盐、溶剂合物或前药，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X、Y和m的定义如本文所述。还提供了包含该化合物的组合物、使用该化合物的方法以及制备该化合物的方法。
• BENZOXAZINE DERIVATIVES AND USES THEREOF
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1694656A1

  公开（公告）日：2006-08-30
• US7202241B2
  申请人：——

  公开号：US7202241B2

  公开（公告）日：2007-04-10
• [EN] BENZOXAZINE DERIVATIVES AND USES THEREOF<br/>[FR] DERIVES DE BENZOXAZINE ET UTILISATIONS DE CEUX-CI
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005058847A1

  公开（公告）日：2005-06-30

  Compounds of the formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, X, Y and m are as defined herein. Also provided are compositions containing these compounds, the use of these compounds for the manufacture of medicaments as well as methods for preparing compound of formula (I).
• 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists
  作者：Shu-Hai Zhao、Jacob Berger、Robin D. Clark、Steven G. Sethofer、Nancy E. Krauss、Julie M. Brothers、Renee S. Martin、Dinah L. Misner、Dietmar Schwab、Ludmila Alexandrova

  DOI：10.1016/j.bmcl.2006.12.093

  日期：2007.6

  A series of novel 3,4-dihydro-2H-benzo[1,4]oxazine derivatives has been designed and synthesized as 5-HT6 receptor antagonists. Many of the compounds displayed subnanomolar affinities for the 5-HT6 receptor and good brain penetration in rats. The relationship of structure and lipophilicity to hERG inhibition of this series of compounds is discussed. (c) 2007 Elsevier Ltd. All rights reserved.